• A Kennett, J Hardy, S Shah, and R A'Hern.
• The Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK. alison.kennett@rmh.nthames.nhs.uk
• Support Care Cancer. 2005 Sep 1; 13 (9): 715-21.

IntroductionNausea and vomiting are distressing symptoms affecting between 20% and 70% of patients with advanced cancer. Methotrimeprazine is a phenothiazine antipsychotic used in palliative care for the management of terminal agitation and nausea/vomiting but there is only anecdotal evidence to support its use in palliative care.AimTo establish whether nausea/vomiting in palliative care patients is improved by the administration of low-dose methotrimeprazine.MethodsPatients with advanced malignancy were entered at different treatment levels according to symptom severity. The dose was altered according to response (minimum dose 6.25 mg daily po, maximum 25 mg by 24-h subcutaneous infusion). Symptoms and side effects were recorded daily from 0 (baseline) to day 5 using a four-point scale. Any improvement in nausea/vomiting score was taken as a response.ResultsSixty-five patients were entered. The cause of nausea and vomiting was multifactorial in the majority of patients, 35/65 (54%). As expected in a study of patients with poor performance status, the attrition rate was high. Of 53 patients evaluable for response at day 2, 33 (62%) showed some improvement in nausea or vomiting. At day 5, improvement was seen in 20/34 (58%). There was no significant change in "side effects" from baseline with time.ConclusionThese results suggest that methotrimeprazine has antiemetic activity.

25 keywords...

hide…